Author:
Tetzlaff Michael T.,Nagarajan Priyadharsini,Chon Susan,Huen Auris,Diab Adi,Omar Pacha,Aung Phyu P.,Torres-Cabala Carlos A.,Mays Steven R.,Prieto Victor G.,Curry Jonathan L.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Dermatology,General Medicine,Pathology and Forensic Medicine
Reference20 articles.
1. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med.,2015
2. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer;Gettinger;J Clin Oncol.,2015
3. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N Engl J Med.,2012
4. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial;Weber;Lancet Oncol.,2015
5. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis;Abdel-Rahman;Future Oncol.,2015
Cited by
98 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献